Federal investigators say that a Chinese drug manufacturer, previously on the Food and Drug Administration’s list of preapproved foreign companies allowed to import GLP-1 ingredients, was able to bring in batches of the weight loss drug from an unauthorized supplier and introduce the substance of unknown origin into the U.S. drug supply.

In September 2025, now-ousted FDA Commissioner Marty Makary launched a so-called “green list” of overseas facilities permitted to ship active pharmaceutical ingredients for GLP-1 medication into the United States. The list is meant to prevent “potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.”

However, one of the greenlisted companies, Harbin Jixianglong Biotech Co., later received an infraction letter from the FDA determining that the Chinese-based drugmaker circumvented the list’s “safeguards” by purchasing semaglutide peptide, the primary ingredient in Ozempic and Wegovy, from a facility not on the list and relabeling containers of the product as its own brand before shipping off the repackaged batches to U.S. pharmacies.

During an on-site inspection, investigators found that the semaglutide was manufactured in an unnamed lab not registered with the FDA. The infraction letter cited Harbin Jixianglong Biotech’s admission that, due to a high demand for semaglutide in the U.S., the company “occasionally purchased the product externally for resale.”

More here

Tagged: Healthcare BACK TO HOMEPAGE